Sakthi Kumar

Prof. Sakthi Kumar


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Plant Science
Verified
Journal Article
Closed access
RNRemya Nair
Remya Nair
SVSaino Hanna Varghese
Saino Hanna Varghese
BNBaiju G. Nair
Baiju G. Nair
TMT. Maekawa
T. Maekawa
YYY. Yoshida
Y. Yoshida
SKSakthi Kumar
Sakthi Kumar

11 September 2011 in International Journal of Polymer Science
Verified
Journal Article
Open access
PDF file
BDBrahatheeswaran Dhandayuthapani
Brahatheeswaran Dhandayuthapani
YYYasuhiko Yoshida
Yasuhiko Yoshida
TMToru Maekawa
Toru Maekawa
SKSakthi Kumar
Sakthi Kumar
Current strategies of regenerative medicine are focused on the restoration of pathologically altered tissue architectures by transplantation of cells in combination with supportive scaffolds and biomolecules. In recent years, considerable interest has been given to biologically active scaffolds which are based on similar analogs of the extracellular matrix that have induced synthesis of tissues and organs. To restore function or regenerate tissue, a scaffold is necessary that will act as a temporary matrix for cell proliferation and extracellular matrix deposition, with subsequent ingrowth until the tissues are totally restored or regenerated. Scaffolds have been used for tissue engineering such as bone, cartilage, ligament, skin, vascular tissues, neural tissues, and skeletal muscle and as vehicle for the controlled delivery of drugs, proteins, and DNA. Various technologies come together to construct porous scaffolds to regenerate the tissues/organs and also for controlled and targeted release of bioactive agents in tissue engineering applications. In this paper, an overview of the different types of scaffolds with their material properties is discussed. The fabrication technologies for tissue engineering scaffolds, including the basic and conventional techniques to the more recent ones, are tabulated.

5 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAnila Mathew
Anila Mathew
TFTakahiro Fukuda
Takahiro Fukuda
YNYutaka Nagaoka
Yutaka Nagaoka
THTakashi Hasumura
Takashi Hasumura
HMHisao Morimoto
Hisao Morimoto
SKSakthi Kumar
Sakthi Kumar
Alzheimer's disease is a growing concern in the modern world. As the currently available medications are not very promising, there is an increased need for the fabrication of newer drugs. Curcumin is a plant derived compound which has potential activities beneficial for the treatment of Alzheimer's disease. Anti-amyloid activity and anti-oxidant activity of curcumin is highly beneficial for the treatment of Alzheimer's disease. The insolubility of curcumin in water restricts its use to a great extend, which can be overcome by the synthesis of curcumin nanoparticles. In our work, we have successfully synthesized water-soluble PLGA coated- curcumin nanoparticles and characterized it using different techniques. As drug targeting to diseases of cerebral origin are difficult due to the stringency of blood-brain barrier, we have coupled the nanoparticle with Tet-1 peptide, which has the affinity to neurons and possess retrograde transportation properties. Our results suggest that curcumin encapsulated-PLGA nanoparticles are able to destroy amyloid aggregates, exhibit anti-oxidative property and are non-cytotoxic. The encapsulation of the curcumin in PLGA does not destroy its inherent properties and so, the PLGA-curcumin nanoparticles can be used as a drug with multiple functions in treating Alzheimer's disease proving it to be a potential therapeutic tool against this dreaded disease.

21 May 2012 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
AAAthulya Aravind
Athulya Aravind
PJPrashanti Jeyamohan
Prashanti Jeyamohan
RNRemya Nair
Remya Nair
SVSrivani Veeranarayanan
Srivani Veeranarayanan
YNYutaka Nagaoka
Yutaka Nagaoka
SKSakthi Kumar
Sakthi Kumar

29 March 2010 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
AGAswathy Ravindran Girija
Aswathy Ravindran Girija
YYYasuhiko Yoshida
Yasuhiko Yoshida
TMT. Maekawa
T. Maekawa
SKSakthi Kumar
Sakthi Kumar

30 November 2015 in Oncogenesis
Verified
Journal Article
Open access
PDF file
ABA Borah
A Borah
Sreejith RaveendranSreejith Raveendran
Sreejith Raveendran
ARA Rochani
A Rochani
TMT Maekawa
T Maekawa
SKSakthi Kumar
Sakthi Kumar
Extensive cancer research in the past few decades has identified the existence of a rare subpopulation of stem cells in the grove of cancer cells. These cells are known as the cancer stem cells marked by the presence of surface biomarkers, multi-drug resistance pumps and deregulated self-renewal pathways (SRPs). They have a crucial role in provoking cancer cells leading to tumorigenesis and its progressive metastasis. Cancer stem cells (CSCs) are much alike to normal stem cells in their self-renewal mechanisms. However, deregulations in the SRPs are seen in CSCs, making them resistant to conventional chemotherapeutic agents resulting in the tumor recurrence. Current treatment strategies in cancer fail to detect and differentiate the CSCs from their non-tumorigenic progenies owing to absence of specific biomarkers. Now, it has become imperative to understand complex functional biology of CSCs, especially the signaling pathways to design improved treatment strategies to target them. It is hopeful that the SRPs in CSCs offer a promising target to alter their survival strategies and impede their tumorigenic potential. However, there are many perils associated with the direct targeting method by conventional therapeutic agents such as off targets, poor bioavailability and poor cellular distribution. Recent evidences have shown an increased use of small molecule antagonists directly to target these SRPs may lead to severe side-effects. An alternative to solve these issues could be an appropriate nanoformulation. Nanoformulations of these molecules could provide an added advantage for the selective targeting of the pathways especially Hedgehog, Wnt, Notch and B-cell-specific moloney murine leukemia virus integration site 1 in the CSCs while sparing the normal stem cells. Hence, to achieve this goal a complete understanding of the molecular pathways corroborate with the use of holistic nanosystem (nanomaterial inhibition molecule) could possibly be an encouraging direction for future cancer therapy.